Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial
Simon Stewart, Melinda J Carrington, Carla H Swemmer, Craig Anderson, Nicol P Kurstjens, John Amerena, Alex Brown, Louise M Burrell, Ferdinandus J de Looze, Mark Harris, Joseph Hung, Henry Krum, Mark Nelson, Markus Schlaich, Nigel P Stocks, Garry L Jennings
British Medical Journal | BMJ PUBLISHING GROUP | Published : 2012
The VIPER-BP study was sponsored by Novartis Pharmaceuticals Australia. The sponsors participated in discussions on the design and conduct of the study and provided logistical support during the trial. The study statistician (Adrian Esterman, University of South Australia) independently generated analyses on behalf of the other members of the clinical safety and efficacy committee (Colin Johnston, MN, Richard Gerraty) who received remuneration from Novartis Pharmaceuticals Australia as study consultants. The study investigators and sponsor jointly assessed study data. All the investigators received remuneration from Baker IDI for the research component of clinical study activities.All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that all authors had a form of support (as described above) and specific relationships (as described above) with Novartis Pharmaceuticals Australia for the submitted work. SS, GLJ, and MJC are supported by the National Health and Medical Research Council of Australia. VIPER-BP study was supported by the Victoria government's operational infrastructure support program.